Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Neoplasm Metastasis 1Glioblastoma 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × etirinotecan pegol × Clear all
NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Stanford University

Phase 2 Completed
27 enrolled 19 charts
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01876446 2020-03-17

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Completed
38 enrolled 16 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡